New hope for ulcerative colitis patients who failed biologics?
NCT ID NCT07513181
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called ATH-063 in 120 adults with moderate to severe ulcerative colitis who have not responded to or can no longer use biologic therapies. Participants will receive either the drug or a placebo for 12 weeks to see if it can reduce symptoms and inflammation. The goal is to find a new treatment option for this hard-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATH-063 (an experimental drug taken as capsules)
What this could lead to
If successful, this could offer a new treatment option for people with ulcerative colitis who haven't responded to other advanced therapies.
What could go wrong
This is an early Phase 2b study with only 120 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gastroenterology Consultants, P.C.
Roswell, Georgia, 30076, United States
-
Miami Clinical Research
Miami, Florida, 33155, United States